Mahendra Deonarain, Ph.D is a preclinical antibody and antibody conjugate platform innovator with the ability to identify product opportunities and establish oncology product programs. Before joining Antikor Biopharma (previously known as Photobiotics), an antibody-fragment ADC company developing engineered and enhanced antibody fragments as vehicles for ADCs, Deonarain was an academic (PI) and biotechnology entrepreneur in antibody technology establishing 2 start-up companies. Deonarain is also a highly published and internationally-renowned researcher at world top-5 institution.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.